The new in vivo results showed that vemurafenib could not inhibit the growth of B16 melanoma, probably because that the mouse melanoma cell line has no activated mutation in the 11 or 15 exon of the BRAF oncogene.44 This result suggested that our SmIII‐EGCG nanocomplex performed more general therapeutic effects on melanoma with no obvious selection to the gene biomarker. The gene discussed is BRAF; the disease is melanoma.